Related references
Note: Only part of the references are listed.Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer
S. Boeck et al.
BRITISH JOURNAL OF CANCER (2013)
Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients
Yvonne Nadine Fahmueller et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Predictive and prognostic value of circulating nucleosomes and serum biomarkers in patients with metastasized colorectal cancer undergoing Selective Internal Radiation Therapy
Yvonne Nadine Fahmueller et al.
BMC CANCER (2012)
Cancer Statistics, 2012
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2012)
Circulating nucleosomes and biomarkers of immunogenic cell death as predictive and prognostic markers in cancer patients undergoing cytotoxic therapy
Oliver J. Stoetzer et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2012)
Predictive value of immunogenic cell death biomarkers HMGB1, sRAGE, and DNase in liver cancer patients receiving transarterial chemoembolization therapy
Nikolaus Kohles et al.
TUMOR BIOLOGY (2012)
Relevance of circulating nucleosomes and oncological biomarkers for predicting response to transarterial chemoembolization therapy in liver cancer patients
Nikolaus Kohles et al.
BMC CANCER (2011)
Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy
Oliver Kepp et al.
CANCER AND METASTASIS REVIEWS (2011)
2011: the immune hallmarks of cancer
Federica Cavallo et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
High-mobility group box 1 and cancer
Daolin Tang et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS (2010)
Analysis and verification of the HMGB1 signaling pathway
Haijun Gong et al.
BMC BIOINFORMATICS (2010)
Decoding Cell Death Signals in Inflammation and Immunity
Laurence Zitvogel et al.
CELL (2010)
The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival
R. Kang et al.
CELL DEATH AND DIFFERENTIATION (2010)
Application of a Time-Varying Covariate Model to the Analysis of CA 19-9 as Serum Biomarker in Patients with Advanced Pancreatic Cancer
Stefan Boeck et al.
CLINICAL CANCER RESEARCH (2010)
Plasma Nucleosome Levels Might Predict Response to Therapy in Patients With Advanced Non-Small-Cell Lung Cancer
Sachin Kumar et al.
CLINICAL LUNG CANCER (2010)
Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer
Michael Haas et al.
TUMOR BIOLOGY (2010)
Clinical Value of Serum HMGB1 Levels in Early Detection of Recurrent Squamous Cell Carcinoma of Uterine Cervix: Comparison with Serum SCCA, CYFRA21-1, and CEA Levels
Xiugui Sheng et al.
CROATIAN MEDICAL JOURNAL (2009)
Serum cathepsin K and cystatin C concentration in patients with advanced non-small-cell lung cancer during chemotherapy
Wojciech Naumnik et al.
FOLIA HISTOCHEMICA ET CYTOBIOLOGICA (2009)
Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer
David Cunningham et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Serum high mobility group box protein 1 as a clinical marker for non-small cell lung cancer
Guan-Hong Shang et al.
RESPIRATORY MEDICINE (2009)
Meta-analysis of randomized trials: Evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer
Volker Heinemann et al.
BMC CANCER (2008)
Serum high mobility group box chromosomal protein 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma
B. -Q. Cheng et al.
DIGESTIVE AND LIVER DISEASE (2008)
Molecular characteristics of immunogenic cancer cell death
A. Tesniere et al.
CELL DEATH AND DIFFERENTIATION (2008)
High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity
Marco E. Bianchi et al.
IMMUNOLOGICAL REVIEWS (2007)
The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy
Lionel Apetoh et al.
IMMUNOLOGICAL REVIEWS (2007)
High mobility group box I (HMGB1) release from tumor cells after treatment: Implications for development of targeted chemoimmunotherapy
Xiang Da (Eric) Dong et al.
JOURNAL OF IMMUNOTHERAPY (2007)
The extracellular release of HMGB1 during apoptotic cell death
Charles W. Bell et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2006)
Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer
Volker Heinemann et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Consensus report of the International Society of Gastrointestinal Oncology on therapeutic progress in advanced pancreatic cancer
Howard S. Hochster et al.
CANCER (2006)
Soluble Receptor for Advanced Glycation End Products: From Disease Marker to Potential Therapeutic Target
Diego Geroldi et al.
CURRENT MEDICINAL CHEMISTRY (2006)
Nucleosomes in colorectal cancer patients during radiochemotherapy
Andreas Kremer et al.
TUMOR BIOLOGY (2006)
Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer
Stefan Boeck et al.
ONCOLOGY (2006)
Cell-free DNA in serum and plasma: Comparison of ELISA and quantitative PCR
S Holdenrieder et al.
CLINICAL CHEMISTRY (2005)
Expression of receptor for advanced glycation end products and HMGB1/amphoterin in colorectal adenomas
T Sasahira et al.
VIRCHOWS ARCHIV (2005)
Nucleosomes in pancreatic cancer patients during radiochemotherapy
A Kremer et al.
TUMOR BIOLOGY (2005)
Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer
H Kuniyasu et al.
JOURNAL OF PATHOLOGY (2002)
Nucleosomes in serum as a marker for cell death
S Holdenrieder et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2001)
Share Paper
